Provention Bio, Inc. clinical trials
Acquired by Sanofi, Apr 27, 2023 · source ↗
The registry lists 9 studies whose lead sponsor is Provention Bio, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 3, 2026.
- 9studies on the registry
- 0open to participants now
- 1reach primary completion within a year
Before and after it joined Sanofi
- First submitted before Provention Bio, Inc. became part of Sanofi
- 9
- First submitted after Provention Bio, Inc. became part of Sanofi
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Provention Bio, Inc.’s studies test, most studies first; none is open now — 2 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- teplizumab1 in phase 30 open · 2
- 0 open · 1
Coming up
1 of Provention Bio, Inc.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- 1NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
All 9 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 18
- 19
- 420
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Provention Bio, Inc.5 studies
- Provention Bio, a Sanofi Company4 studies
Something wrong with this grouping? Tell us on the Sanofi page.
Studies
Recruiting first, then most recently updated. Showing 9 of 9. All Sanofi studies →
- PRV-3279-2a Trial in Systemic LupusTerminatedNCT05087628Phase 2
Sponsor listed in the registry: Provention Bio, a Sanofi Company · First submitted before Provention Bio became part of Sanofi
- Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)Active, not recruitingNCT04598893
Sponsor listed in the registry: Provention Bio, a Sanofi Company · First submitted before Provention Bio became part of Sanofi
- PRV-015 in Gluten-free Diet Non-responsive Celiac DiseaseCompletedNCT04424927Phase 2
Sponsor listed in the registry: Provention Bio, a Sanofi Company · First submitted before Provention Bio became part of Sanofi
- At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)CompletedNCT04270942Phase 2
Sponsor listed in the registry: Provention Bio, a Sanofi Company · First submitted before Provention Bio became part of Sanofi
- Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of TeplizumabCompletedNCT03875729Phase 3
Sponsor listed in the registry: Provention Bio, Inc. · First submitted before Provention Bio, Inc. became part of Sanofi
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy SubjectsCompletedNCT03955666Phase 1
Sponsor listed in the registry: Provention Bio, Inc. · First submitted before Provention Bio, Inc. became part of Sanofi
- PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteersCompletedNCT04690426Phase 1
Sponsor listed in the registry: Provention Bio, Inc. · First submitted before Provention Bio, Inc. became part of Sanofi
- Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's DiseaseCompletedNCT03854305Phase 2
Sponsor listed in the registry: Provention Bio, Inc. · First submitted before Provention Bio, Inc. became part of Sanofi
- A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative ColitisCompletedNCT03849599Phase 1
Sponsor listed in the registry: Provention Bio, Inc. · First submitted before Provention Bio, Inc. became part of Sanofi